|
Gender
| |
|
Female
|
152 (100)
|
|
Male
|
0 (0)
|
|
Age
| |
|
≤55
|
80 (52.6)
|
|
>55
|
72 (47.4)
|
|
Mean (±SD)
|
56.0 (12.4)
|
|
Tumor size (T-status)
| |
|
T1 (0–20 mm)
|
77 (50.7)
|
|
T2 (20–50 mm)
|
68 (44.7)
|
|
T3 (>50 mm)
|
7 (4.6)
|
|
(T2-T3)
|
(75 (49.3))
|
|
Grade
| |
|
G1 (well differentiated)
|
21 (13.8)
|
|
G2 (moderately differentiated)
|
53 (34.9)
|
|
(G1-G2)
|
(74 (48.7))
|
|
G3 (poorly differentiated)
|
78 (51.3)
|
|
Estrogen receptor (ER) status
| |
|
Negative
|
35 (23.0)
|
|
Positive
|
117 (77.0)
|
|
Progesterone receptor (PR) status
| |
|
Negative
|
51 (33.6)
|
|
Positive
|
101 (66.4)
|
|
Human epidermal growth factor receptor 2 (HER2) status
|
|
Negative
|
137 (90.1)
|
|
Positive
|
15 (9.9)
|
|
Hormone receptor (HR) negative status (ER/PR negative)
|
|
Yes
|
34 (22.4)
|
|
No
|
118 (77.6)
|
|
Triple negative (TN) status (ER/PR/HER2 negative)
| |
|
Yes
|
29 (19.1)
|
|
No
|
123 (80.9)
|
|
Lymph node (N) status
| |
|
N0 (0 lymph nodes)
|
98 (64.5)
|
|
N1 (1–3 lymph nodes)
|
40 (26.3)
|
|
N2 (4–9 lymph nodes)
|
11 (7.2)
|
|
N3 (≥10 lymph nodes)
|
3 (2.0)
|
|
(N1-N2-N3)a
|
(54 (35.5))
|
|
Molecular tumor subtypes (PAM50 signatures)
| |
|
Basal
|
25 (16.7)
|
|
HER2 enriched
|
15 (10.0)
|
|
Luminal A
|
63 (42.0)
|
|
Luminal B
|
39 (26.0)
|
|
Normal-like
|
8 (5.3)
|
